Anj Saha

Anj joined Interline Therapeutics in January 2021. Prior to that he was an EIR at 5AM Ventures, where he was involved with several early seed companies. Previously, he was at Nurix Therapeutics, where he built and headed the Lead Discovery department. There his team helped discover and progress first in class small molecules against novel E3 ligases and degraders in the fields of oncology and immuno-oncology that are currently in clinical and pre-clinical development. Prior to Nurix, Anj was Director of Biology at Proteostasis Therapeutics and started his industry career at GlaxoSmithKline as an Investigator within Cancer Research.

Anj completed his undergraduate studies in India at IIT-Delhi and received a Ph.D. in Biochemistry working on chromatin biology with Prof. Bradley Cairns at University of Utah. He completed postdoctoral training as a Leukemia and Lymphoma Society Fellow working on ubiquitin ligases with Prof. Raymond Deshaies at Caltech.